Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
This work supports the potential use of miR-122 as biomarker of human DILI when measured in a capillary blood drop.
|
28257154 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Serum miRNA-122 combined with albumin accurately identified subjects who died within 6 months of drug induced liver injury.
|
27860186 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Conclusion: GLDH appears to be more useful than miR-122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event.
|
29357190 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Certain serum biomarkers, like miR-122, may have clinical utility in early-presenting patients with either intrinsic or idiosyncratic DILI in the future, while others likely will not find use.
|
30080986 |
2018 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We were also able to demonstrate that, although miR-122 is present in greater quantities in exosome-free form, both exosome-bound and non-vesicle bound miR-122 are released in a similar profile throughout the course of DILI.
|
27978773 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Sensitivity of miR-122 in diagnosing DILI was [0.85 (95% CI, 0.75-0.91), I = 53.46%] and specificity was [0.93 (95% CI, 0.86-0.97), I = 65.10%], the area under ROC curve was 0.95 (95% CI, 0.93-0.97).
|
30544438 |
2018 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
However, miR-122-5p, -192-5p, -34a-5p and -22-3p demonstrated a much more significant induction in patients with hepatocellular DILI, thus revealing better specificity for hepatocellular damage.
|
31198949 |
2020 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, the proposed biosensor exhibited excellent specificity and recovery in spiked serum samples, and was successfully used for detecting miR-122 in real biological samples, which provided a rapid and efficient method for detecting drug-induced liver injury at an early stage.
|
29156406 |
2018 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Studies of new serum biomarkers such as glutamate dehydrogenase, high mobility group box protein 1, and microRNA-122 could provide information for use in diagnosis and prognosis and provide important insights into the mechanisms of the pathogenesis of DILI.
|
24389305 |
2014 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
MiR-122 as a biomarker also has the potential to bridge results in in vitro experiments to in vivo animal models and human samples using the same assay, and to link findings from clinical studies in determining the relevance of in vitro models being developed for the study of drug-induced liver injury.
|
25527335 |
2015 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Areas covered: This review highlights the shortcomings of the currently used panel of biomarkers and how miRNAs, primarily miR-122, show an improved level of specificity and sensitivity in the prediction of DILI.
|
29235390 |
2018 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury.
|
28678845 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Serum microRNA-122-3p, microRNA-194-5p and microRNA-5099 are potential toxicological biomarkers for the hepatotoxicity induced by Airpotato yam.
|
28844483 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury.
|
26489516 |
2015 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Circulating microRNAs as potential markers of human drug-induced liver injury.
|
22045675 |
2011 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Recently, circulating microRNAs (miRNAs) such as miR-122 and miR-192 have emerged as promising biomarkers of liver injury in preclinical species and in DILI patients.
|
25359176 |
2015 |
Drug-Induced Liver Disease
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
MiR-122 as a biomarker also has the potential to bridge results in in vitro experiments to in vivo animal models and human samples using the same assay, and to link findings from clinical studies in determining the relevance of in vitro models being developed for the study of drug-induced liver injury.
|
25527335 |
2015 |